Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Original Article

. 2017; 8(3): 78-82


Association of Polymorphisms in CYP2C19 with the Efficacy of Clopidogrel Therapy in South Indian Patients Undergoing Percutaneous Coronary Intervention

Nuthalapati Rama Kumari, Ravella Keerthika, Murki Naveen Kumar, Jahangeer Basha, Konda Kumaraswami, Indukuri Bhaskara Raju, Vijay Kumar Kutala.

Abstract
Background: The dual antiplatelet therapy (DAPT) with aspirin and clopidogrel has been considered as the standard of
care in the setting of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Recent evidence
supports a role of loss-of-function (LOF) variants in the CYP2C19 as a determinant of clopidogrel response. Carriers of
the CYP2C19*2 LOF allele has found to have the reduced pharmacodynamic response to clopidogrel and worse clinical
outcome as compared with non-carriers in Asian countries including Indian population. However, it is unknown whether
the time course of the antiplatelet effects of clopidogrel differs according to CYP2C19 genotype in South Indian patients
with ACS. Methods: We assessed the platelet reactivity in the early and late phases of ACS according to CYP2C19 genotypes.
Eighty six consecutive in-patients who were admitted with ACS at our center were enrolled in the study. The determination
of platelet aggregation was done by using a platelet aggregometer and genetic analysis was done by PCR-RFLP
method. Results: The numbers of patients carrying the CYP2C19*1/*1 (extensive metabolizer, EM), *1/*2 (Intermediate
metabolizer, IM), *2/*2 (poor metabolizer PM), genotypes were 22 (30.9%), 37 (52.1%), 12 (16.9%), respectively. Time
course of platelet aggregation from baseline to the late phase among the 3 genotypes indicate that there was statistically
significant at 30th day of treatment (p=0.004) between wild versus hetero and homozygous variant alleles. The
percentage of patients shifted to prasugrel from clopidogrel due to non-response were 4 (8%), 11(29%), 6 (50%) in wild,
heterozygous and homozygous variant alleles. In homozygous group, we found 4 out of 6 patients developed acute stent
thrombosis within one week of PCI. Conclusion: We observed that the CYP2C19*2 and CYP2C19*1/*2 are the major
determinants of clopidogrel efficacy. Acute stent thrombosis was observed in patients carrying CYP2C19*2 variant allele

Key words: Antiplatelet therapy, Acute coronary syndrome, Percutanous coronary intervention, Clopidogrel, Pharmacogenetics.


Full-text options

Full-text Article




Advertisement


SUBMIT YOUR ARTICLE NOW




ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.